News & Events
In the news
Clean Mails – Décembre 2024
Exosomes: Your new therapeutic vectors
With the experience accumulated by the team for more than 20 years on viral-based products, Naobios perceives the development and manufacturing of exosomes as a natural extension of our capabilities. It is thus our goal to expand activities in this field, sustained by our strict segregation policies and cleaning procedures.
Press Release – Sumagen – October 2024
Naobios and Sumagen successfully optimize HIV vaccine candidate for industrial production
Key milestone reached within expected initial timelines with successful set up of cell growth and production of HIV-1 vaccine candidate at bench scale. Phase I/II trial to assess safety and efficacy expected to start after cGMP production end of 2025.
Press Release – October 2024
Naobios and European Vaccine Initiative partner up to manufacture Respiratory Syncytial Virus (RSV) challenge agent
Collaboration will support Controlled Human Infection Model (CHIM) studies to accelerate development of effective and affordable RSV vaccines
Clean Mails – June 2024
Considerations around oncolytic virus manufacturing
Naobios gathers 20 years of expertise spanning the whole range of virus- and vector-based therapies. Within state-of-the-art cGMP facilities, Naobios supports companies with diverse oncolytic virus manufacturing needs, addressing all hurdles typically encountered by sponsors.
Press Release – April 2024
Naobios and Sumagen sign exclusive partnership to develop HIV vaccine
Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials...
Save the date !
Congresses 2024: meet our teams!
Teams at Naobios are traveling the world to attend major conferences and congresses within the biotech sector. As leaders of the biopharma field, our mission and our drive at the Clean Biologics group are to remain both reachable and up-to-date with regards to the latest developments and innovations.
Clean Mails – February 2024
Extending biomanufacturing capacity for human challenge studies
Backed by a $1.87M (€1.7M) grant from the Bill & Melinda Gates Foundation, Naobios is proud to announce the extension of biomanufacturing capacities to generate viral agents for human viral challenge agents (HVCA), providing the support to this growing evaluation strategy.
Press Release – December 2023
Naobios receives $1.87M (€1.7M) in support of vaccine development
Grant to fund manufacture of human viral challenge agent used in accelerating the vaccine development process